The flu treatment Relenza looks unlikely to be made available on the National
ÎçÒ¹¸£Àû1000¼¯ºÏ Service in Britain. As New Scientist went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Are Neanderthals descendants of modern humans?
2
Neanderthal infants were enormous compared with modern humans
3
How autoimmune conditions can unexpectedly drive mental illness
4
Collapse of key ocean current may release billions of tonnes of carbon
5
Exclusive report: Inside Chernobyl, 40 years after nuclear disaster
6
Largest ever map of universe captures 47 million galaxies and quasars
7
The biggest threat to Chernobyl is no longer radiation
8
From autism to migraines, birth order may have wide-reaching effects
9
The man who crawls into the perilous heart of the Chernobyl reactor
10
A key solution to climate change isn't happening – and that's good
